

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Stearns
Jorge A. Goldstein
David K.S. Connell
Robert W. Leonard
Tacy-Gene G. Durkin
Michelle A. Cimbala
Michael R. Roy
Robert L. Scholz
Eric K. Staffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Robert C. Millington
Donald L. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Patrick E. Garrett

Jeffrey L. Hechey
Eldora L. Ellison
Thomas C. Fida
Donald R. Banowitz
Peter A. Jackson
Jeffrey S. Wheeler
Brian J. Del Buono
Mark Fox Evans
Edward W. Yee
Vincent L. Caputo
Virgil Lee Neuman
Theodore A. Wood
Elizabeth J. Humes
Joseph S. Orsini
Frank R. Cottingham
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Inacy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchet
Timothy A. Doyle
Gail L. Longworth
Lori A. Gordon
Laura A. Vogel
Brian S. Woods
Babai M.S. Ali
Shannon A. Carroll
Arthur E. Choi
Michelle K. Hakoubet
Martha A. Rose
Young Tang
Christopher J. Webb

W. Blake Gohmert
James J. Pohl
John T. Naran
Mark W. Rygiel
Kevin W. McCabe
Michael R. Mulet

Registered Patent Agents
Karen R. Martowicz
Matthew J. Dowd
Karinna Nijman Pei Quach
Soyan L. Shelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Eldon
Julie A. Weider
Mia Mulheijer

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Loring
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass II
Marvin C. Gutrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to Federal Agencies

IFW

September 15, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8782
INTERNET ADDRESS:
RCOBLENT@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1645

Re: U.S. Utility Patent Application No. 10/521,010
U.S. National Phase of Appl. No. PCT/AU2003/000910
Int'l Filing Date: July 14, 2003
For: **Expression of Hydrophobic Proteins**
Inventors: Elizabeth Ann WEBB *et al.*
Our Ref: 2349.0010000/JUK/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (1 page) citing seven (7) documents (US1 and FP1-FP6);
3. Copies of six (6) cited documents (FP1-FP6);
4. Form PTO/SB/08B (1 page) citing four (4) documents (NPL1-NPL4);
5. Copies of four (4) cited documents (NPL1-NPL4); and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents

September 15, 2006

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



William B. Coblenz
Attorney for Applicants
Registration No. 57,104

JUK/WBC:cpn

Enclosures

58325_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Elizabeth Ann WEBB *et al.*

Appl. No.: 10/521,010

Int'l Filing Date: July 14, 2003

For: **Expression of Hydrophobic
Proteins**

Confirmation No.: 2794

Art Unit: 1645

Examiner: *To Be Assigned*

Atty. Docket: 2349.0010000/JUK/WBC

**Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(b)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1-FP6** and **NPL1-NPL4** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of the U.S. patent, document **US1**, cited on the attached Form PTO/SB/08A is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



William B. Coblentz
Attorney for Applicants
Registration No. 57,104

Date: September 15, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

530481_1.DOC



Approved for use through 07/31/2006.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for ~~Form~~ 449/PTO

(Use as many sheets as necessary)

Application Number	10/521,010
Int'l Filing Date	July 14, 2003
First Named Inventor	Elizabeth Ann WEBB
Art Unit	<i>To Be Assigned</i>
Examiner Name	<i>To Be Assigned</i>
Attorney Docket Number	2349.0010000/Л/К/В/С

Sheet	1	of	1
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	FP1	WO 96/03144 A1	02/08/1996	The Council of the Queensland Institute of Medical Research <i>et al.</i>		
	FP2	WO 97/05164 A1	02/13/1997	CSL Limited <i>et al.</i>		
	FP3	WO 99/55730 A1	11/04/1999	Chiron S.P.A., <i>et al.</i>		
	FP4	WO 00/63693 A1	10/26/2000	Kokotus		
	FP5	WO 01/19408 A1	03/22/2001	Zycos Inc., <i>et al.</i>		
	FP6	WO 01/47541 A1	07/05/2001	Epimmune, Inc., <i>et al.</i>		

530487 1:DOC

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov/mpep/901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard 3.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if the English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/



PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/521,010
				Int'l Filing Date	July 14, 2003
				First Named Inventor	Elizabeth Ann WEBB
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	2349.0010000/JUK/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Deavin, A.J., et al., "Statistical Comparison of Established T-Cell Epitope Predictors Against a Large Database of Human and Murine Antigens," <i>Mol. Immunol.</i> 33:145-155, Elsevier Science Ltd. (1996)	
	NPL2	Firat, H., et al., "Design of a polypeptide construct for the induction of HLA-A*0201-restricted HIV-1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice," <i>Eur. J. Immunol.</i> 31:3064-3074, Wiley-VCH Verlag GmbH (October 2001)	
	NPL3	Le, T.T.T., et al., "Cytotoxic T cell polypeptide vaccines delivered by ISCOMs," <i>Vaccine</i> 19:4669-4675, Elsevier Science Ltd. (September 2001)	
	NPL4	Shi, Y.P., et al., "Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate," <i>Vaccine</i> 18:2902-2914, Elsevier Science Ltd. (2000)	

530488_1.DOC

Examiner Signature	/Michael Bortin/	Date Considered	07/18/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/